Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a clinical-stage biopharmaceutical company developing drug candidates for inflammatory diseases, including kidney and respiratory diseases, with a focus on new kidney therapies in areas with unmet medical needs. The Company pursues new product concepts and applies scientific knowledge to the discovery of products from early-stage development through to commercialisation. Its products are DMX-652 for Acute Kidney Injury and DMX-200 for Focal Segmental Glomerulosclerosis (FSGS). The Company operates in one segment, being investment in research and development of biopharmaceutical drugs.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
15
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,897.00 | 59.20 | -0.66% |
| CAC 40 | 8,097.95 | 25.46 | -0.31% |
| DAX 40 | 25,326.15 | 84.48 | -0.33% |
| Dow JONES (US) | 51,511.59 | 352.10 | -0.68% |
| FTSE 100 | 10,683.97 | 21.29 | -0.20% |
| HKSE | 24,754.39 | 79.73 | -0.32% |
| NASDAQ | 26,936.04 | 308.24 | -1.13% |
| Nikkei 225 | 65,513.99 | 495.04 | 0.76% |
| NZX 50 Index | 13,824.83 | 3.07 | 0.02% |
| S&P 500 | 7,706.03 | 58.61 | -0.75% |
| S&P/ASX 200 | 8,702.00 | 63.30 | -0.72% |
| SSE Composite Index | 3,888.37 | 48.15 | -1.22% |